Skip to main content
OpenTrials
Not Yet Recruiting

NCT Number: NCT06572761

A Combination of Antibiotics to Decrease Neonatal Morbidity and Mortality for Previable Threatened Labor

The purpose of this study is to determine whether a combination of antibiotics (cephalosporin 3rd generation, clarithromycin, metronidazole) are effective to prolong pregnancies complicated with previable threatened labour with intact membranes.

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Age range

18 year and older

Sex eligibility

Female

Study type

Interventional

Phase

Phase 3

Primary location

Centre Hospitalier Poissy-Saint Germain

Poissy, 78300, France

Location contact

Thibaud QUIBEL, MD, PhD

CONTACT

0178636012

About this study

Observational data suggest that subclinical infectious conditions can lead to spontaneous preterm labor. 10% of births are premature, but the morbidity/mortality of premature babies is concentrated mainly among newborns born before 30 weeks of gestation or weighing less than 1500 g. The relationship to infection/inflammation and premature birth is not constant throughout pregnancy, but this infectious risk increases the earlier the gestational age of spontaneous labor is (before 30 weeks). The pathogens that have the strongest associations with premature birth are Gardnerella vaginalis, Ureaplasma urealyticum and Mycoplasma hominis, but also Streptococcus B, Escherichia coli, Klebsiella spp, or Haemophilus influenzae.

Antibiotic treatment to treat an intra-amniotic infection is considered ineffective. Indeed, the last randomized trial (Oracle 2, 2001), which studied several antibiotic regimens for threatened premature delivery with intact membranes, did not find a significant reduction in neonatal morbidity/mortality after administration of co-beta-lactam, erythromycin or the combination of both. In addition, this large trial dominates the results of the latest Cochrane meta-analysis which evaluated preventive antibiotic therapy to stop premature labor with intact membranes.

Recently, it has been showed that a new combination of antibiotics (ceftriaxone, clarithromycin and metronidazole) reduced the risk of infection and intra-amniotic inflammation in preterm labor with intact membranes. This retrospective study deserves to be confirmed by a randomized study

The investigator's goal is to study whether a new combination of antibiotics in a very limited population of pregnancies complicated by the threat of late miscarriage would make it possible to prolong pregnancies in order to improve neonatal outcomes.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Threatened previable prelabor with intact membranes between 18weeks of gestation +0/7 and 23 weeks of gestation 6/7 SA defined on endovaginal ultrasound by a short cervix ≤10 mm, and/or protrusion of the membranes on speculum examination.
  • Maternal age >18 years
  • Affiliated with social security
  • Correct understanding of the French language
  • Singleton pregnancy
  • Foetus alive at time of inclusion
  • Absence of regular and painful uterine contractions

Exclusion criteria

  • Premature labor defined by regular, painful uterine contractions and a short cervix
  • Protected person (patient under guardianship/curatorship/or legal protection)
  • Multiple pregnancies
  • Premature rupture of membranes
  • Acute chorioamnionitis
  • Contraindication to protocol antibiotics
  • Chromosomal abnormality, congenital malformation
  • Patients who received antibiotics before randomization, or requiring antibiotics for another indication (chorioamnionitis, pyelonephritis, etc.)
  • Participation in another research (Specify the category: RIPH, EC, IC, etc.) or being in the exclusion period following previous research involving humans, if applicable
  • Patient under AME (if no exemption from affiliation)

Treatment and study plan

Combination of antibiotics

Drug

Ceftriaxone : 1g/day parenteral clarithromycin 500 mg*2/day orally metronidazole 500mg*3/ day orally

Other names: Ceftriaxone; clarithromycin, metronidazole

Emergency cerclage

Device

Emergency cerclage

vaginal progesterone

Drug

Vaginal progesterone

Primary outcomes

  1. A perinatal composite outcome

    Time frame: Up to 24 weeks

    • Late miscarriage
    • Perinatal mortality
    • Bronchodysplasia,
    • Sepsis proven by blood culture,
    • Intraventricular hemorrhage ≥3,
    • Periventricular leukomalacia ≥2,
    • Ulcero-necrotizing enterocolitis at stage ≥2 according to the Bell classification.

Secondary outcomes

  1. Gestationnal age at delivery

    Time frame: 6 months

    • Gestationnal age at delivery ≥ 24 weeks of gestation (wg) 0/7, 28 wg0/7, 32 wg0/7, 34 wg0/7 et 37 wg0/7
    • Latency period between randomisation and delivery (≥2 days, ≥7 days, ≥14 days et ≥28 days)
  2. Maternal Morbidty

    Time frame: 6 months

    Chorioamniotitis, postpartum endometritis , sepsis proven par positive hemocultures

  3. Bacteriological

    Time frame: 6 months

    Acquisition of multi-resistant germs during childbirth

Study contacts

Contact information is provided by the study sponsor or research team.

Charly LARRIEU

CONTACT

[email protected]

01 58 41 34 78

Thibaud QUIBEL, MD, PhD

CONTACT

[email protected]

0178636012

Sponsors and collaborators

Lead sponsor

Assistance Publique - Hôpitaux de Paris

Other

Collaborators

  • URC-CIC Paris Descartes Necker Cochin

Registry information

Official study title

A Combination of Antibiotics to Decrease Neonatal Mortality and Morbidity for Pregnancies Complicated With Previable Labour and Intact Membranes: a Multicenter, Open-label, Randomized and Controlled Trial

Acronym: ECHEC-MAT

Important dates

Study start
2026
Primary completion
2030
Study completion
2030
First posted
Aug 27, 2024
Registry last updated
May 1, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.